
### [NCIT:C27885](http://purl.obolibrary.org/obo/NCIT_C27885)
**Label:** Infiltrating Bladder Urothelial Carcinoma

**Subclasses:** [NCIT:C39819](http://purl.obolibrary.org/obo/NCIT_C39819) (Infiltrating Bladder Urothelial Carcinoma, Nested Variant), [NCIT:C39829](http://purl.obolibrary.org/obo/NCIT_C39829) (Infiltrating Bladder Urothelial Carcinoma with Giant Cells), [NCIT:C39818](http://purl.obolibrary.org/obo/NCIT_C39818) (Infiltrating Bladder Urothelial Carcinoma with Trophoblastic Differentiation), [NCIT:C8940](http://purl.obolibrary.org/obo/NCIT_C8940) (Stage III Bladder Urothelial Carcinoma), [NCIT:C8941](http://purl.obolibrary.org/obo/NCIT_C8941) (Stage IV Bladder Urothelial Carcinoma), [NCIT:C6191](http://purl.obolibrary.org/obo/NCIT_C6191) (Stage I Bladder Urothelial Carcinoma), [NCIT:C39820](http://purl.obolibrary.org/obo/NCIT_C39820) (Infiltrating Bladder Urothelial Carcinoma, Microcystic Variant), [NCIT:C39826](http://purl.obolibrary.org/obo/NCIT_C39826) (Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant without Heterologous Elements), [NCIT:C39825](http://purl.obolibrary.org/obo/NCIT_C39825) (Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant with Heterologous Elements), [NCIT:C39817](http://purl.obolibrary.org/obo/NCIT_C39817) (Infiltrating Bladder Urothelial Carcinoma with Glandular Differentiation), [NCIT:C39816](http://purl.obolibrary.org/obo/NCIT_C39816) (Infiltrating Bladder Urothelial Carcinoma with Squamous Differentiation), [NCIT:C39821](http://purl.obolibrary.org/obo/NCIT_C39821) (Infiltrating Bladder Lymphoepithelioma-Like Carcinoma), [NCIT:C8939](http://purl.obolibrary.org/obo/NCIT_C8939) (Stage II Bladder Urothelial Carcinoma), [NCIT:C39824](http://purl.obolibrary.org/obo/NCIT_C39824) (Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant), 

**Class expressions from DL-Learner:**

- [NCIT:C3910](http://purl.obolibrary.org/obo/NCIT_C3910) (Molecular Abnormality) 56.62%
- [NCIT:C36286](http://purl.obolibrary.org/obo/NCIT_C36286) (Urinary System Finding) and [NCIT:C5035](http://purl.obolibrary.org/obo/NCIT_C5035) (Genitourinary Signs and Symptoms) 54.00%
- [NCIT:C100104](http://purl.obolibrary.org/obo/NCIT_C100104) (Sign or Symptom) and [NCIT:C36286](http://purl.obolibrary.org/obo/NCIT_C36286) (Urinary System Finding) 54.00%
- Thing 53.25%
- [NCIT:C39875](http://purl.obolibrary.org/obo/NCIT_C39875) (Loss of Chromosome 9q) 52.00%
- [NCIT:C39716](http://purl.obolibrary.org/obo/NCIT_C39716) (EGFR Protein Overexpression) 52.00%
- [NCIT:C36681](http://purl.obolibrary.org/obo/NCIT_C36681) (MDM2 Gene Amplification) 52.00%
- [NCIT:C36679](http://purl.obolibrary.org/obo/NCIT_C36679) (HRAS Gene Amplification) 52.00%
- [NCIT:C36652](http://purl.obolibrary.org/obo/NCIT_C36652) (CCND1 Gene Amplification) 52.00%
- [NCIT:C36649](http://purl.obolibrary.org/obo/NCIT_C36649) (EGFR Gene Amplification) 52.00%
- [NCIT:C36639](http://purl.obolibrary.org/obo/NCIT_C36639) (ERBB2 Protein Overexpression) 52.00%
- [NCIT:C36638](http://purl.obolibrary.org/obo/NCIT_C36638) (ERBB2 Gene Amplification) 52.00%
- [NCIT:C36636](http://purl.obolibrary.org/obo/NCIT_C36636) (Loss of Chromosome 9p) 52.00%
- [NCIT:C36599](http://purl.obolibrary.org/obo/NCIT_C36599) (Loss of Chromosome Y) 52.00%
- [NCIT:C36548](http://purl.obolibrary.org/obo/NCIT_C36548) (Loss of Chromosome 2q) 52.00%


